 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C₂₈H₃₈O₆ |
| Molecular Weight | 470.60 |
| Exact Mass | 470.267 |
| CAS # | 161115-59-9 |
| Related CAS # | Ciclesonide;126544-47-6 |
| PubChem CID | 6918281 |
| Appearance | White to off-white solid powder |
| Density | 1.284g/cm3 |
| Boiling Point | 640.778ºC at 760 mmHg |
| Melting Point | 129-132ºC |
| Flash Point | 211.522ºC |
| LogP | 3.497 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 34 |
| Complexity | 949 |
| Defined Atom Stereocenter Count | 9 |
| SMILES | C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(O[C@@H](O4)C5CCCCC5)C(=O)CO)CCC6=CC(=O)C=C[C@]36C)O |
| InChi Key | OXPLANUPKBHPMS-ZXBNPROVSA-N |
| InChi Code | InChI=1S/C28H38O6/c1-26-11-10-18(30)12-17(26)8-9-19-20-13-23-28(22(32)15-29,27(20,2)14-21(31)24(19)26)34-25(33-23)16-6-4-3-5-7-16/h10-12,16,19-21,23-25,29,31H,3-9,13-15H2,1-2H3/t19-,20-,21-,23+,24+,25+,26-,27-,28+/m0/s1 |
| Chemical Name | (1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one |
| Synonyms | CIC-AP Ciclesonide active principle |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Ciclesonide is an inhaled corticosteroid with limited affinity for the glucocorticoid receptor and, when converted to the active metabolite isobutyrylciclesonide, is particularly effective in downregulating the pro-inflammatory activity of airway parenchymal cells in vitro . 0.3-3.0 μM ciclesonide and desisobutyryl-ciclesonide can dose-dependently reduce the proliferation of peripheral blood mononuclear cells against Candida albicans, but the inhibitory action of desisobutyryl-ciclesonide is more strong. high. Significant proliferation of PhlP5 was only observed in cultures from atopic subjects: effective downregulation was detected at 0.03 μM ciclesonide and 0.003 μM deisobutyrylciclesonide (at 3 μM ciclesonide De and 0.03 μM deisobutyryl ciclesonide fully stopped). 3 μM Ciclesonide and Desisobutyryl-ciclesonide inhibited PhlP5-specific T cell blast growth and the fraction of interleukin-4-producing cells. In PBMC cultures from atopic patients, both ciclesonide (CIC) and desisobutyrylciclesonide (des-CIC) elicited a dose-dependent downregulation of PhlP5-driven proliferation. The effect of 0.03 μM ciclesonide and 0.003 μM desisobutyrylciclesonide was already substantial (p<0.001 for each comparison) and was observed at 3 μM ciclesonide and 0.03 μM desisobutyrylciclesonide Completely inhibited at early stage. The inhibitory action of Desisobutyryl-ciclesonide at 0.003 μM (p<0.05), 0.03 μM (p<0.001) and 0.3 μM (p<0.05) on PhlP5-induced PBMC proliferation was stronger than that of Ciclesonide [1]. |
| References |
[1]. Ciclesonide modulates in vitro allergen-driven activation of blood mononuclear cells and allergen-specific T-cell blasts. Immunol Lett. 2012 Jan 30;141(2):190-6. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~212.49 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1249 mL | 10.6247 mL | 21.2495 mL | |
| 5 mM | 0.4250 mL | 2.1249 mL | 4.2499 mL | |
| 10 mM | 0.2125 mL | 1.0625 mL | 2.1249 mL |